Application of polypeptide in preparation of medicine for relieving hepatic ischemia-reperfusion injury
Through the combination of specific peptide sequences and permeasured peptides, the problem of liver ischemia and reperfusion injury in liver transplantation is solved, which significantly reduces the risk of liver damage and functional failure, and provides a new prevention and treatment strategy for liver transplantation surgery.
Patent Information
- Application Number
- CN202410880546.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-02
- Publication Date
- 2024-11-19
AI Technical Summary
The inevitable liver ischemia and reperfusion injury during liver transplant surgery leads to impaired liver function, increasing the risk of early liver failure and multi-organ failure, and it is difficult to effectively prevent and treat the existing technology.
The specific polypeptide sequence AVPEGFVIPRGNVL and its structural chemical structure are used, combined with the membrane-permeable peptide GRKKRRQRRRPPQQ, as a drug to alleviate liver ischemia and reperfusion damage by reducing tissue cell structure destruction, reducing ALT and AST levels and reducing the number of apoptotic cells.
Effectively alleviate the destruction of tissue cells after liver ischemia and reperfusion injury, reduce the serum ALT and AST levels, reduce the number of apoptotic cells in the liver, and provide a new prevention and treatment strategy for liver transplant surgery.
Smart Images

Figure CN118976094A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to application of a polypeptide in preparing a drug for alleviating liver ischemia-reperfusion injury. Background Art
[0002] End-stage liver disease is a growing cause of death worldwide, with a mortality rate of over 50%. In most cases, liver transplantation is the only effective treatment for end-stage liver disease. Hepatic ischemia-reperfusion injury (HIRI) is inevitable in liver transplantation and significantly affects liver function after liver transplantation. Hepatic ischemia-reperfusion injury (HIRI) is an important pathophysiological event in liver trauma, partial liver resection or transplantation. It is a phenomenon in which the liver is further damaged after blood supply is interrupted and then restored, aggravating the initial damage caused by ischemia. It is a major risk factor for early liver failure and the resulting multiple organ failure in patients undergoing liver transplantation, leading to high morbidity and mortality. Therefore, it is urgent to actively develop effective HIRI prevention and treatment strategies. Summary of the invention
[0003] The purpose of the present invention is to provide a polypeptide for use in preparing a drug for alleviating liver ischemia-reperfusion injury in view of the deficiencies in the prior art.
[0004] To achieve the above object, the technical solution adopted by the present invention is:
[0005] Provided is a use of a polypeptide in preparing a drug for alleviating liver ischemia-reperfusion injury, wherein the amino acid sequence of the polypeptide is shown in SEQ ID NO.1: AVPEGFVIPRGNVL, and the structural chemical formula thereof is shown in formula (I):
[0006]
[0007]
[0008] Furthermore, at least one end of the polypeptide is connected to a cell-penetrating peptide, and the amino acid sequence of the cell-penetrating peptide is shown in SEQ ID NO.2: GRKKRRQRRRPPQQ.
[0009] Furthermore, the drug for reducing liver ischemia-reperfusion injury also includes a pharmaceutically acceptable carrier and / or excipient.
[0010] Furthermore, the polypeptide can alleviate the destruction of tissue cell structure after liver ischemia-reperfusion injury.
[0011] Furthermore, the polypeptide can reduce the levels of ALT and AST in serum after liver ischemia-reperfusion injury.
[0012] Furthermore, the polypeptide can reduce the number of apoptotic cells in the liver after liver ischemia-reperfusion injury.
[0013] The present invention adopts the above technical solution, and has the following technical effects compared with the prior art:
[0014] The present invention proves that the polypeptide as shown in formula (I) can reduce the destruction of tissue cell structure after liver ischemia-reperfusion injury, can reduce the levels of ALT and AST in serum after liver ischemia-reperfusion injury, can reduce the number of apoptotic cells in the liver after liver ischemia-reperfusion injury, and provides a new strategy for reducing liver ischemia-reperfusion injury in liver transplantation surgery. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 is the chemical structural formula of the polypeptide of the present invention.
[0016] Figure 2 A shows that the polypeptide of formula (I) can increase the cell viability of AML12 cells; Figure 2 B shows that the polypeptide can increase the cell viability of AML12 cells after hypoxia-reoxygenation treatment.
[0017] Figure 3 It was shown that the polypeptide of formula (I) reduces the number of apoptotic cells in hypoxia / reoxygenation experiments.
[0018] Figure 4 It was shown that the polypeptide of formula (I) increased the expression of KI67 in AML12 and also increased the expression of KI67 in AML12 after hypoxia / reoxygenation.
[0019] Figure 5 It is shown that the polypeptide of formula (I) alleviates the destruction of tissue cell structure after ischemia-reperfusion injury in mouse liver.
[0020] Figure 6 It is shown that the polypeptide of formula (I) reduces the ALT and AST levels in the serum of mice after liver ischemia-reperfusion injury; wherein A is the ALT level; and B is the AST level.
[0021] Figure 7 It was shown that the polypeptide of formula (I) reduces the number of apoptotic cells in the liver after ischemia-reperfusion injury in mice. DETAILED DESCRIPTION
[0022] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments, but is not intended to be limiting of the present invention. It should be noted that the embodiments and features in the embodiments of the present invention may be combined with each other without conflict.
[0023] The present invention collects liver specimens from 6 liver transplant patients before and after transplantation, uses liquid chromatography tandem-mass spectrometry (LC-MS / MS) to identify the polypeptide spectrum in the liver, takes the pre-transplantation as the control, and records the differentially expressed polypeptides up-regulated and down-regulated in the liver after transplantation. Then, peptides that may alleviate liver ischemia-reperfusion injury are screened out using peptideomics and bioinformatics methods. The amino acid sequence of the finally screened polypeptide is shown in SEQ ID NO.1: AVPEGFVIP RGNVL, and its structural chemical formula is shown in formula (Ⅰ), and it is named HLTP1 (Human Liver Transplantation Peptide 1):
[0024]
[0025] Furthermore, at least one end of the polypeptide is connected to a cell-penetrating peptide, and the amino acid sequence of the cell-penetrating peptide is shown in SEQ ID NO.2: GRKKRRQRRRPPQQ.
[0026] Verification Example 1 In vitro cell experiment
[0027] 1.1 AML12 cells (FH0338, FuHeng) in the logarithmic growth phase were digested with trypsin until the cells naturally fell off the bottom of the culture dish, and then culture medium (FH-AML12, FuHeng) was added to terminate the digestion. The cells were collected into a centrifuge tube and centrifuged at 1000r / min for 3 minutes. The supernatant was discarded and the cell density was diluted to 1*10 with culture medium. 5 The cell suspension was then added to a 96-well plate at 100 μl per well and placed in a 37°C, 5% CO2 incubator for 24 h.
[0028] The culture medium in the 96-well plate was aspirated, and the peptide (Shanghai Ketide Biotechnology Co., Ltd.) was prepared with culture medium at 0 μM, 1 μM, 3 μM, 10 μM, 30 μM, and 100 μM, added to the 96-well plate, and acted on AML12 cells for 1 hour. The culture medium was discarded, and sugar-free DMEM / F12 culture medium was added, and the cells were cultured in a hypoxic incubator for 6 hours. The culture medium was discarded, and normal culture medium was added, and the cells were cultured in a normal incubator for 6 hours.
[0029] CCK8 reagent was added to each well of a 96-well plate at 10 μl and incubated at 37°C for 2 h.
[0030] The absorbance at 450 nm was detected using an enzyme-labeled instrument, and the data were analyzed and the cell viability was calculated.
[0031] Results Reference Figure 2 When the polypeptide of formula (I) was added, the activity of AML12 cells was significantly increased.
[0032] 1.2 AML12 cells in the logarithmic growth phase were digested with trypsin until the cells naturally fell off the bottom of the culture dish, and then the culture medium was added to terminate the digestion. The cells were collected into a centrifuge tube and centrifuged at 1000r / min for 3 minutes. The supernatant was discarded, and the cells were resuspended in the culture medium. The cell suspension was added to a 6-well plate and incubated in a 37°C, 5% CO2 incubator for 24 hours. The cells were stained with a TUNEL kit (APExBio, K1134) and observed under a microscope.
[0033] Results Reference Figure 3 When a polypeptide of formula (I) is added, the number of apoptotic cells in AML12 cells after hypoxia / reoxygenation treatment is reduced.
[0034] 1.3 Digest AML12 cells in the logarithmic growth phase with trypsin until the cells naturally fall off the bottom of the culture dish, then add culture medium to stop digestion. Collect cells into a centrifuge tube and centrifuge at 1000r / min for 3 minutes. Discard the supernatant, resuspend the cells with culture medium, add the cell suspension to a fluorescent dish, and incubate in a 37°C, 5% CO2 incubator for 24 hours. Observe and photograph using a microscope after immunofluorescence staining of cells with KI67 (abcam, 16667).
[0035] Results Reference Figure 4 When a polypeptide of formula (I) is added, the proliferation of AML12 cells increases after hypoxia / reoxygenation treatment.
[0036] Verification Example 2 Animal Experiment
[0037] The peptide was injected into C57BL / 6 mice (Spefor (Suzhou) Biotechnology Co., Ltd.) at a concentration of 5 mg / kg (diluted with physiological saline) through the tail vein 1 hour before surgery. A 70% liver local ischemia-reperfusion injury model was established by minimally invasively clamping the liver vessels for 60 minutes and then releasing the vascular clamp. The mice were then humanely killed, and the mouse plasma and liver were collected to measure the serological and histological indicators in the liver. The specific groups are as follows:
[0038] Group 1: saline pretreatment, non-ischemia / reperfusion group.
[0039] Group 2: peptides pretreatment, non-ischemia / reperfusion group.
[0040] Group 3: saline pretreatment, ischemia / reperfusion group.
[0041] Group 4: peptides pretreatment, ischemia / reperfusion group.
[0042] The results are as follows Figure 5and Figure 6 As shown, the polypeptide alleviates the destruction of tissue cell structure after ischemia-reperfusion injury in mouse liver, and reduces the levels of ALT and AST in serum after ischemia-reperfusion injury in mouse liver.
[0043] and Figure 7 The results showed that the peptide reduced the number of apoptotic cells in liver tissue after ischemia-reperfusion injury in mice.
[0044] The above description is only a preferred embodiment of the present invention, and does not limit the implementation mode and protection scope of the present invention. For those skilled in the art, it should be aware that all solutions obtained by equivalent substitutions and obvious changes made using the contents of the specification and illustrations of the present invention should be included in the protection scope of the present invention.
Claims
1. Use of a polypeptide in the preparation of a drug for alleviating liver ischemia-reperfusion injury, It is characterized in that The amino acid sequence of the polypeptide is shown in SEQ ID NO.1: AVPEGFVIPRGNVL, and its structural chemical formula is shown in formula (I):
2. The use according to claim 1, It is characterized in that At least one end of the polypeptide is also connected to a cell-penetrating peptide, and the amino acid sequence of the cell-penetrating peptide is shown in SEQ ID NO.2: GRKKRRQRRRPPQQ.
3. The use according to claim 1, It is characterized in that The drug for reducing liver ischemia-reperfusion injury also includes a pharmaceutically acceptable carrier and / or adjuvant.
4. The use according to claim 1, It is characterized in that The polypeptide can alleviate the destruction of tissue cell structure after liver ischemia-reperfusion injury.
5. The use according to claim 1, It is characterized in that The polypeptide can reduce the levels of ALT and AST in serum after liver ischemia-reperfusion injury.
6. The use according to claim 1, It is characterized in that The polypeptide can reduce the number of apoptotic cells in the liver after liver ischemia-reperfusion injury.
